MEDICAL
Compiled by Leslie Berkman, Times staff writer
Viratek Inc., a subsidiary of Costa Mesa-based ICN Pharmaceuticals Inc., said its drug Virazole (ribavirin) has been approved for marketing in three more countries for the treatment of hospitalized infants and children with respiratory syncytial virus. The most recent approvals came from the Netherlands, Belgium and Singapore. The company also has authorization to market the drug for the same illness in the United Kingdom, Spain, Canada and Australia. The U.S. Food and Drug Administration approved marketing the drug in the United States in 1985.
